{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Donepezil+Hydrochloride+%28Aricept%29&page=2",
    "query": {
      "intervention": "Donepezil Hydrochloride (Aricept)",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 149,
    "total_pages": 15,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Donepezil+Hydrochloride+%28Aricept%29&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Donepezil+Hydrochloride+%28Aricept%29&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-08T17:14:09.263Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00766363",
      "title": "Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alzheimer's Disease",
        "Central Nervous System Diseases"
      ],
      "interventions": [
        {
          "name": "EVP-6124 (0.1 mg/day)",
          "type": "DRUG"
        },
        {
          "name": "EVP-6124 (0.3 mg/day)",
          "type": "DRUG"
        },
        {
          "name": "EVP-6124 (1.0 mg/day)",
          "type": "DRUG"
        },
        {
          "name": "Comparator: Placebo",
          "type": "DRUG"
        },
        {
          "name": "Donepezil",
          "type": "DRUG"
        },
        {
          "name": "Rivastigmine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "FORUM Pharmaceuticals Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "50 Years to 90 Years"
      },
      "enrollment_count": 49,
      "start_date": "2008-10",
      "completion_date": "2009-03",
      "has_results": true,
      "last_update_posted_date": "2012-04-20",
      "last_synced_at": "2026-10-08T17:14:09.263Z",
      "location_count": 4,
      "location_summary": "San Diego, California • Hallandale, Florida • Berlin, New Jersey + 1 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Hallandale",
          "state": "Florida"
        },
        {
          "city": "Berlin",
          "state": "New Jersey"
        },
        {
          "city": "Princeton",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00766363"
    },
    {
      "nct_id": "NCT00675025",
      "title": "Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Down Syndrome"
      ],
      "interventions": [
        {
          "name": "Donepezil hydrochloride (Aricept)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "10 Years to 17 Years"
      },
      "enrollment_count": 117,
      "start_date": "2008-04-04",
      "completion_date": "2008-12-15",
      "has_results": true,
      "last_update_posted_date": "2021-03-29",
      "last_synced_at": "2026-10-08T17:14:09.263Z",
      "location_count": 31,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 24 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00675025"
    },
    {
      "nct_id": "NCT02670161",
      "title": "Quality Improvement and Practice Based Research in Neurology Using the EMR",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Brain Tumors",
        "Epilepsy",
        "Migraine",
        "Mild Cognitive Impairment",
        "Concussion",
        "Multiple Sclerosis",
        "Neuropathy",
        "Parkinson's",
        "Restless Legs Syndrome",
        "Stroke"
      ],
      "interventions": [
        {
          "name": "Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Endeavor Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 3300,
      "start_date": "2016-05",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2025-08-24",
      "last_synced_at": "2026-10-08T17:14:09.263Z",
      "location_count": 1,
      "location_summary": "Evanston, Illinois",
      "locations": [
        {
          "city": "Evanston",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02670161"
    },
    {
      "nct_id": "NCT06518941",
      "title": "An Open Trial of a Novel Pharmacotherapy for Habit Modification in Anorexia Nervosa",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anorexia Nervosa"
      ],
      "interventions": [
        {
          "name": "Donepezil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "New York State Psychiatric Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 10,
      "start_date": "2027-01",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-08-03",
      "last_synced_at": "2026-10-08T17:14:09.263Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06518941"
    },
    {
      "nct_id": "NCT02079246",
      "title": "Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Idalopirdine 60 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lundbeck A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 1463,
      "start_date": "2014-04-07",
      "completion_date": "2017-07-06",
      "has_results": true,
      "last_update_posted_date": "2018-08-10",
      "last_synced_at": "2026-10-08T17:14:09.263Z",
      "location_count": 64,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 56 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Carlsbad",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02079246"
    },
    {
      "nct_id": "NCT01712074",
      "title": "Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "PF-05212377 (SAM-760)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 186,
      "start_date": "2012-11",
      "completion_date": "2015-09",
      "has_results": true,
      "last_update_posted_date": "2017-03-20",
      "last_synced_at": "2026-10-08T17:14:09.263Z",
      "location_count": 40,
      "location_summary": "Costa Mesa, California • Imperial, California • Rancho Mirage, California + 29 more",
      "locations": [
        {
          "city": "Costa Mesa",
          "state": "California"
        },
        {
          "city": "Imperial",
          "state": "California"
        },
        {
          "city": "Rancho Mirage",
          "state": "California"
        },
        {
          "city": "Santa Ana",
          "state": "California"
        },
        {
          "city": "Hamden",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01712074"
    },
    {
      "nct_id": "NCT02696512",
      "title": "A Study of IBRF Disorders of Consciousness Advanced Care/MultiModal Care Protocol in Severe Disorders of Consciousness",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Brain Injury"
      ],
      "interventions": [
        {
          "name": "Polypharmacy using FDA-approved products",
          "type": "DRUG"
        },
        {
          "name": "Median Nerve Stimulation (MNS)",
          "type": "DEVICE"
        },
        {
          "name": "Nutraceutical Supplementation",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Standard of Care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE",
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "International Brain Research Foundation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 30,
      "start_date": "2016-03",
      "completion_date": "2017-04",
      "has_results": false,
      "last_update_posted_date": "2016-09-02",
      "last_synced_at": "2026-10-08T17:14:09.263Z",
      "location_count": 1,
      "location_summary": "Edison, New Jersey",
      "locations": [
        {
          "city": "Edison",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02696512"
    },
    {
      "nct_id": "NCT00070161",
      "title": "Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors",
        "Radiation Toxicity"
      ],
      "interventions": [
        {
          "name": "EGb761",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "donepezil hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "cognitive assessment",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 68,
      "start_date": "2001-07-01",
      "completion_date": "2012-08-01",
      "has_results": false,
      "last_update_posted_date": "2021-09-09",
      "last_synced_at": "2026-10-08T17:14:09.263Z",
      "location_count": 4,
      "location_summary": "Phoenix, Arizona • Rome, Georgia • Winston-Salem, North Carolina + 1 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Rome",
          "state": "Georgia"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        },
        {
          "city": "Spartanburg",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00070161"
    },
    {
      "nct_id": "NCT01466088",
      "title": "Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Donepezil",
          "type": "DRUG"
        },
        {
          "name": "AZD3480",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Targacept Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "60 Years to 85 Years"
      },
      "enrollment_count": 386,
      "start_date": "2011-10",
      "completion_date": "2014-05",
      "has_results": false,
      "last_update_posted_date": "2015-06-03",
      "last_synced_at": "2026-10-08T17:14:09.263Z",
      "location_count": 3,
      "location_summary": "Phoenix, Arizona • Brooksville, Florida • Hallandale, Florida",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Brooksville",
          "state": "Florida"
        },
        {
          "city": "Hallandale",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01466088"
    },
    {
      "nct_id": "NCT03030105",
      "title": "Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "BPN14770",
          "type": "DRUG"
        },
        {
          "name": "BPN14770 placebo",
          "type": "DRUG"
        },
        {
          "name": "Donepezil",
          "type": "DRUG"
        },
        {
          "name": "Donepezil placebo",
          "type": "DRUG"
        },
        {
          "name": "Scopolamine 0.6 MG/ML",
          "type": "DRUG"
        },
        {
          "name": "Scopolamine placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tetra Discovery Partners",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 38,
      "start_date": "2017-01",
      "completion_date": "2017-06",
      "has_results": false,
      "last_update_posted_date": "2018-10-16",
      "last_synced_at": "2026-10-08T17:14:09.263Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03030105"
    }
  ]
}